Inflammatory bowel disease: II. Gene mapping

Molecular Genetics and Metabolism

Volumn 74, Issue 1-2, 2001, Pages 22-44

  Taylor, Kent D ^a   Yang, Huiying ^a   Rotter, Jerome I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NOTCH RECEPTOR; PROTHROMBIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; CHROMOSOME 16; CHROMOSOME 6; CROHN DISEASE; ENTERITIS; GENE LOCUS; GENE MAPPING; GENETIC LINKAGE; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; MARKER GENE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SHORT SURVEY; STATISTICAL ANALYSIS; ULCERATIVE COLITIS;

ANIMALIA;

EID: 0034793755     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.2001.3214     Document Type: Article

References (157)

1. Diabetes mellitus
2. Mapping complex genetic traits in humans
3. Chromosomal assignment of human and rat hypertension candidate genes: Type I angiotensin II receptor genes and the SA gene
4. Mapping complex genetic traits in humans: New methods using a complete RFLP linkage map
5. Assessing the role of HLA-linked and unlinked determinants of disease
6. Genetic aspects of idiopathic inflammatory bowel disease
7. Familial empiric risks for inflammatory bowel disease: Differences between Jews and non-Jews
8. The epidemiology of idiopathic inflammatory bowel disease
9. Mapping of a susceptibility locus for Crohn's disease on chromosome 16 by a genome-wide nonparametric linkage analysis
10. Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not in ulcerative colitis
11. Susceptibility loci in inflammatory bowel disease
12. Evidence of linkage of the inflammatory bowel disease susceptibility locus on chromosome 16 (IBD1) to ulcerative colitis
13. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: Evidence for epistasis between 1p and IBD1
14. Analysis of Australian Crohn's disease pedigrees refines the localization for susceptibility to inflammatory bowel disease on chromosome 16
15. Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16
16. American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12
17. Fine mapping of the inflammatory bowel disease susceptibility locus 1 (IBD1) in the pericentromeric region of chromosome 16
18. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12
19. Linkage and association between inflammatory bowel disease and a locus on chromosome 12
20. Additional evidence of linkage between Crohn's disease and a putative locus on chromosome 12
21. Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses
22. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort
23. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci
24. A genome-wide search identifies potential new susceptibility loci for Crohn's disease
25. High-density genome scan in Crohn disease shows confirmed linkage to chromosme 14q11-12
26. The IBD International Genetics Consortium. Compelling evidence for a chromosome 16 locus in Crohn's disease: An international collaboration
27. Confirmation of a susceptibility locus for Crohn's disease on chromosome 16
28. Genome-wide scanning in inflammatory bowel diseases
29. No evidence for linkage on chromsomes 16-12-7 and 3 in the Belgian population may reflect genetic heterogeneity of inflammatory bowel disease
30. Absence of linkage between inflammatory bowel disease and selected loci on chromosomes 3, 7, 12, and 16
31. Precision mapping of chromosome 12 linkage in IBD: Evidence for a haplotype association
32. The interferon-gamma gene as a positional and functional candidate gene for inflammatory bowel disease
33. Vitamin D receptor gene polymorphism further evidence for an association with Crohn's disease
34. Comprehensive human genetic maps: Individual and sex-specific variation in recombination
35. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease
36. Linkage analyses of chromosome 6 loci, including HLA, in familial aggregations of Crohn disease
37. Analysis of the contribution of HLA genes to genetic predisposition in inflammatory bowel disease
38. Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity
39. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function
40. Analysis of a positional candidate gene for inflammatory bowel disease: NRAMP2
41. Linkage of inflammatory bowel disease to human chromosome 6p
42. Replication of linkage on 14q11-12 in inflammatory bowel disease
43. Genetic analysis of susceptibility to dextran sulfate sodium-induced colitis in mice
44. Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease
45. Fine mapping the IBD linkage on chromosome 3
46. Absence of GNAI2 codon 179 oncogene mutations in inflammatory bowel disease
47. Crohn's disease and ulcerative colitis are associated with the DNA repair gene MLH1
48. Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3
49. Alterations in mucosal content of colonic glycoconjugates in inflammatory bowel disease defined by monoclonal antibodies
50. Complete sequence and gene map of a human major histocompatibility complex
51. HLA-DR and -DQ phenotypes in inflammatory bowel disease: A meta-analysis
52. Association of HLA class II genes with susceptibility to Crohn's disease
53. Polymorphisms in tumour necrosis factor and adhesion molecule genes in patients with inflammatory bowel disease: Associations with HLA-DR and -DQ alleles and subclinical markers
54. HLA class II gene frequencies in Crohn's disease: A population based analysis in Germany
55. Genetic markers may predict disease behavior in patients with ulcerative colitis
56. Genetic markers in clinically well defined patients with ulcerative colitis (UC)
57. HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish caucasian populations
58. Association of the human lymphocyte-DR2 antigen with Japanese ulcerative colitis
59. Distinct associations of HLA class II genes with inflammatory bowel disease
60. Ulcerative colitis: A genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (anti-neutrophil cytoplasmic antibodies) markers
61. HLA-DRB1*1502 allele, subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression
62. Molecularly defined HLA-DR2 alleles in ulcerative colitis and an antineutrophil cytoplasmic antibody-positive subgroup
63. Analysis of MHC class II DP, DQ and DR alleles in Crohn's disease
64. HLA-linked susceptibility and resistance genes in Crohn's disease
65. An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele
66. Evidence for genetic heterogeneity in inflammatory bowel disease (IBD); HLA genes in the predisposition to suffer from ulcerative colitis (UC) and Crohn's disease (CD)
67. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease
68. Notch signaling: Cell fate control and signal integration in development
69. Notch as a mediator of cell fate determination in hematopoiesis: Evidence and speculation
70. Getting to the guts of enteroendocrine differentiation
71. Regulation of T cell fate by Notch
72. Linkage disequilibrium mapping identifies a class III major histocompatibility complex (MHC) susceptibility haplotype to Crohn's disease in Ashkenazi Jews
73. Specific clinical and immunological features in Crohn's disease patients are associated with the MHC class III marker Notch4
74. Tumour necrosis factor and Crohn's disease
75. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
76. The tumor necrosis factor ligand and receptor families
77. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription
78. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans
79. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria
80. Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles
81. Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases
82. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease
83. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection
84. Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis
85. DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. Numerous TNF/lymphotoxin alleles tagged by two closely linked microsatellites in the upstream region of the lymphotoxin (TNF-beta) gene
86. Highly informative typing of the human TNF locus using six adjacent polymorphic markers
87. Dense Alu clustering and a potential new member of the NF kappa B family within a 90 kilobase HLA class III segment
88. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6
89. Polymorphism at position -1031 in the TNF gene confers susceptibility to Crohn's disease
90. Characterization of genomic and functional variation throughout the TNF gene in patients with IBD
91. Factors associated with differential clinical responses to treatment with anti-TNF antibody (Infliximab): ANCA pattern and LTA haplotype
92. Tumor necrosis factor microsatellite haplotype A11B4C1D3E3 is associated with anti-saccharomyces cerevisiae antibody (ASCA) across clinical forms of inflammatory bowel disease
93. The role of interleukin-1 in disease
94. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation
95. Imbalance of the interleukin 1 system in colonic mucosa-association with intestinal inflammation and interleukin 1 receptor antagonist genotype 2
96. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis
97. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis
98. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1
99. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist
100. Cytokine gene polymorphisms in inflammatory bowel disease
101. Significance of interleukin-1beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases
102. Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease
103. Significant differences in the interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in a Hungarian population with inflammatory bowel disease
104. IL 1B gene polymorphisms influence the course and severity of inflammatory bowel disease
105. Adhesion molecules - Their role in health and disease
106. Role of cell adhesion molecules in inflammatory bowel diseases
107. In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells
108. Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease
109. Circulating soluble adhesion molecules in inflammatory bowel disease
110. Antibodies to intercellular adhesion molecule-1 ameliorate the inflammatory response in acetic acid-induced inflammatory bowel disease
111. Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease
112. A causative relationship between mutant IFNGR1 alleles and impaired cellular response to IFNG in a compound heterozygous child
113. In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma
114. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection
115. Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis
116. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection
117. Chronic pouchitis after ileal pouch-anal anastomosis for ulcerative colitis (UC) is associated with the interferon gamma receptor alpha gene independent of perinuclear antineutrophil cytoplasmic antibody (pANCA) level
118. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications
119. Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease
120. Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis
121. Macrophage NRAMP1 and its role in resistance to microbial infections
122. Identifying genetic susceptibility factors for tuberculosis in Africans: A combined approach using a candidate gene study and a genome-wide screen
123. The natural resistance-associated macrophage protein and susceptibility to intracellular pathogens
124. The natural resistance-associated macrophage protein gene is associated with Crohn's disease
125. Experimental models of inflammatory bowel disease
126. Experimental models to study molecular mechanisms underlying intestinal inflammation
127. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis
128. The germ-free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats
129. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats
130. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli
131. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies
132. DAREmutant mice
133. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene
134. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation
135. Alteration of gene expression by intestinal epithelial cells precedes colitis in interleukin-2-deficient mice
136. High expression of inducible nitric oxide synthase correlates with intestinal inflammation of interleukin-2-deficient mice
137. Dysregulated intrathymic development in the IL-2-deficient mouse leads to colitis-inducing thymocytes
138. Induction and prevention of colonic inflammation in IL-2-deficient mice
139. Administration of mAb against alpha E beta 7 prevents and ameliorates immunization-induced colitis in IL-2-/- mice
140. Interleukin-10-deficient mice develop chronic enterocolitis
141. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice
142. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses
143. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism
144. Immune and inflammatory responses in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response
145. Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor
146. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice
147. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment
148. Role of cytokines in the early stages of chronic colitis in TCR alpha-mutant mice
149. The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice
150. Mucosal immunity and inflammation. II. The yin and yang of T cells in intestinal inflammation: Pathogenic and protective roles in a mouse colitis model
151. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells
152. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells
153. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation
154. A role for NK cells as regulators of CD4+ T cells in a transfer model of colitis
155. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice
156. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells
157. CD45RBhigh CD4+ T cells from IFN-gamma knockout mice do not induce wasting disease